Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Hyloris Pharmaceuticals SA

HYL.BR ✓ COMPLIANTFree checks used up today ☆ Track — members

Europe · Healthcare · Pharmaceuticals ·

Belgium Micro Cap Analyst: BUY

Last Close

$4.22

▼ -0.26%

Market Cap $114.08M · Vol 3.42K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$114.08M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

-27.34%

YoY

RSI (14)

37.31

Momentum

Beta

1.02

vs Market

52W High

$9.40

57.16% below

52W Low

$3.78

11.94% above

Volume

3.42K

Avg 7.84K

P/B

7.23

Price-to-book

ROE

-22.88%

Return on equity

Free Float

43.38%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Hyloris Pharmaceuticals SA (HYL.BR) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HYL.BR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.29%

-10.24%

-19.96%

-22.27%

YTD

-44.88%

-34.09%

-68.79%

-77.43%

Financials & Valuation

TTM · Annual

Total Revenue	$8.46M
Net Income	$-7,438,075.00
Revenue Growth (YoY)	+55.60%
Gross Margin	94.74%
Operating Margin	-111.41%
Net Profit Margin	-87.87%
ROE	-22.88%
ROA · ROIC	-17.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	26.57
P/B	7.23
P/FCF	N/A
EPS Growth	-27.34%
Outstanding Shares	28.00M

Technical Indicators

50-Day SMA	$4.66
200-Day SMA	$5.76
RSI (14)	37.31
Beta	1.02
52-Week High	$9.40
52-Week Low	$3.78

Volume Today	3.42K
Avg Daily Volume (30D)	7.84K
Relative Volume	0.44x
Volatility (10D)	46.10
Volatility (30D)	57.99
Free Float	43.38%

Analyst Consensus

BUY

Current Price $4.22

Mean Target $12.78

52W Low$3.78 52W High$9.40

Current

Target

$3.78 $9.40

Current Analyst target

+202.92% upside potential · 3 analysts

Identifiers

ExchangeEurope

FIGIBBG00TLBS8D6

ISINBE0974363955

CountryBelgium

Sub-IndustryPharmaceuticals (NEC)

Earnings DateDec 24, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company -0.11% JNJ Johnson & Johnson -1.62% ABBV AbbVie Inc. -0.98% NVS Novartis AG -1.40% NOVN.S Novartis AG -0.02%

Company Profile

Hyloris Pharmaceuticals SA is a Belgium-based bio-pharmaceutical company. The Company focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. It has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. It also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.